Rethinking Aspergillosis in the Era of Microbiota and Mycobiota.
Antagonistic interactions
Aspergillosis
Microbiota
Mycobiota
Synergism
Journal
Mycopathologia
ISSN: 1573-0832
Titre abrégé: Mycopathologia
Pays: Netherlands
ID NLM: 7505689
Informations de publication
Date de publication:
12 Jun 2024
12 Jun 2024
Historique:
received:
10
10
2023
accepted:
09
04
2024
medline:
12
6
2024
pubmed:
12
6
2024
entrez:
12
6
2024
Statut:
epublish
Résumé
Aspergillosis encompasses a wide range of clinical conditions based on the interaction between Aspergillus and the host. It ranges from colonization to invasive aspergillosis. The human lung provides an entry door for Aspergillus. Aspergillus has virulence characteristics such as conidia, rapid growth at body temperature, and the production of specific proteins, carbohydrates, and secondary metabolites that allow A. fumigatus to infiltrate the lung's alveoli and cause invasive aspergillosis. Alveolar epithelial cells play an important role in both fungus clearance and immune cell recruitment via cytokine release. Although the innate immune system quickly clears conidia in immunocompetent hosts, A. fumigatus has evolved multiple virulence factors in order to escape immune response such as ROS detoxifying enzymes, the rodlet layer, DHN-melanin and toxins. Bacterial co-infections or interactions can alter the immune response, impact Aspergillus growth and virulence, enhance biofilm formation, confound diagnosis, and reduce treatment efficacy. The gut microbiome's makeup influences pulmonary immune responses generated by A. fumigatus infection and vice versa. The real-time PCR for Aspergillus DNA detection might be a particularly useful tool to diagnose pulmonary aspergillosis. Metagenomics analyses allow quick and easy detection and identification of a great variety of fungi in different clinical samples, although optimization is still required particularly for the use of NGS techniques. This review will analyze the current state of aspergillosis in light of recent discoveries in the microbiota and mycobiota.
Identifiants
pubmed: 38864956
doi: 10.1007/s11046-024-00853-2
pii: 10.1007/s11046-024-00853-2
doi:
Substances chimiques
Virulence Factors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
49Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Bongomin F, Gago S, Oladele R, Denning D. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi. 2017;3(4):57.
doi: 10.3390/jof3040057
Fisher MC, Hawkins NJ, Sanglard D, Gurr SJ. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science. 2018;360(6390):739–42.
pubmed: 29773744
doi: 10.1126/science.aap7999
Guinea J, Torres-Narbona M, Gijón P, Muñoz P, Pozo F, Peláez T, et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect. 2010;16(7):870–7.
pubmed: 19906275
doi: 10.1111/j.1469-0691.2009.03015.x
Rodrigues ML, Nosanchuk JD. Fungal diseases as neglected pathogens: A wake-up call to public health officials. Reynolds TB, editor. PLOS Negl Trop Dis. 2020; 14(2):7964.
Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol. 2004;42(10):4419–31.
pubmed: 15472288
pmcid: 522363
doi: 10.1128/JCM.42.10.4419-4431.2004
Tabarsi P, Sharifynia S, Pourabdollah Toutkaboni M, Abtahian Z, Rahdar M, Mirahmadian AS, Hakamifard A. Coinfection by Aspergillus and Mucoraceae species in two cases of acute rhinosinusitis as a complication of COVID-19. Case Rep Med. 2022;2022:8114388.
pubmed: 35299783
pmcid: 8922146
doi: 10.1155/2022/8114388
Nargesi S, Jafarzadeh J, Najafzadeh MJ, Nouripour-Sisakht S, Haghani I, Abastabar M, et al. Molecular identification and antifungal susceptibility of clinically relevant and cryptic species of Aspergillus sections Flavi and Nigri. J Med Microbiol. 2022;71(4):001480.
doi: 10.1099/jmm.0.001480
Peterson SW, Varga J, Frisvad JC, Samson RA. Phylogeny and subgeneric taxonomy of Aspergillus. Welcome to DTU Research Database. Wageningen; 2008. p. 33–56.
Moldoveanu B, Gearhart AM, Jalil BA, Saad M, Guardiola JJ. Pulmonary Aspergillosis: spectrum of disease. Am J Med Sci. 2021;361(4):411–9.
pubmed: 33563417
doi: 10.1016/j.amjms.2020.12.009
Osherov N. Interaction of the pathogenic mold Aspergillus fumigatus with lung epithelial cells. Front Microbiol. 2012;3:346.
pubmed: 23055997
pmcid: 3458433
doi: 10.3389/fmicb.2012.00346
Paulussen C, Hallsworth JE, Álvarez-Pérez S, Nierman WC, Hamill PG, Blain D, et al. Ecology of aspergillosis: insights into the pathogenic potency of Aspergillus fumigatus and some other Aspergillus species. Microb Biotechnol. 2016;10(2):296–322.
pubmed: 27273822
pmcid: 5328810
doi: 10.1111/1751-7915.12367
Russo A, Tiseo G, Falcone M, Menichetti F. Pulmonary aspergillosis: an evolving challenge for diagnosis and treatment. Infect Dis Ther. 2020;9(3):511–24.
pubmed: 32638227
pmcid: 7339098
doi: 10.1007/s40121-020-00315-4
Blickensdorf M, Timme S, Figge MT. Hybrid agent-based modeling of Aspergillus fumigatus infection to quantitatively investigate the role of pores of Kohn in human alveoli. Front Microbiol. 2020;11:1951.
pubmed: 32903715
pmcid: 7438790
doi: 10.3389/fmicb.2020.01951
Arastehfar A, Carvalho A, Houbraken J, Lombardi L, Garcia-Rubio R, Jenks JD, et al. Aspergillus fumigatus and aspergillosis: from basics to clinics. Stud Mycol. 2021;100: 100115.
pubmed: 34035866
pmcid: 8131930
doi: 10.1016/j.simyco.2021.100115
Denning DW, Chakrabarti A. Pulmonary and sinus fungal diseases in non-immunocompromised patients. Lancet Infect Dis. 2017;17(11):e357–66.
pubmed: 28774699
doi: 10.1016/S1473-3099(17)30309-2
Palmieri F, Koutsokera A, Bernasconi E, Junier P, von Garnier C, Ubags N. Recent advances in fungal infections: from lung ecology to therapeutic strategies with a focus on Aspergillus spp. Front Med. 2022; 9–12.
Lowes D, Al-Shair K, Newton PJ, Morris J, Harris C, Rautemaa-Richardson R, et al. Predictors of mortality in chronic pulmonary aspergillosis. Eur Respir J. 2017;49:2.
doi: 10.1183/13993003.01062-2016
Chen H, Zhang X, Zhu L, An N, Jiang Q, Yang Y, Ma D, Yang L, Zhu R. Clinical and immunological characteristics of Aspergillus fumigatus-sensitized asthma and allergic bronchopulmonary aspergillosis. Front Immunol. 2022;13: 939127.
pubmed: 35983066
pmcid: 9379317
doi: 10.3389/fimmu.2022.939127
Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2014;70(3):270–7.
pubmed: 25354514
doi: 10.1136/thoraxjnl-2014-206291
Gago S, Denning DW, Bowyer P. Pathophysiological aspects of Aspergillus colonization in disease. Med Mycol. 2019;57(2):S219–27.
pubmed: 30239804
doi: 10.1093/mmy/myy076
Denning DW, O’Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J. 2006;27(3):615–26.
pubmed: 16507864
doi: 10.1183/09031936.06.00074705
Ofori A, Steinmetz AR, Akaasi J, Asafu Adjaye Frimpong GA, Norman BR, Obeng-Baah J, et al. Pulmonary aspergilloma: an evasive disease. Int J Mycobacteriol. 2016;5(2):235–9.
pubmed: 27242239
doi: 10.1016/j.ijmyco.2016.03.002
Robin C, Cordonnier C, Sitbon K, Raus N, Lortholary O, Maury S, et al. Mainly post-transplant factors are associated with invasive aspergillosis after allogeneic stem cell transplantation: a study from the surveillance des aspergilloses invasives en france and société francophone de greffe de moelle et de thérapie cellulaire. Biol Blood Marrow Transplant. 2019;25(2):354–61.
pubmed: 30268782
doi: 10.1016/j.bbmt.2018.09.028
Koehler P, Cornely OA, Böttiger BW, Dusse F, Eichenauer DA, Fuchs F, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020;63(6):528–34.
pubmed: 32339350
pmcid: 7267243
doi: 10.1111/myc.13096
Kanj A, Abdallah N, Soubani AO. The spectrum of pulmonary aspergillosis. Respir Med. 2018;141:121–31.
pubmed: 30053957
doi: 10.1016/j.rmed.2018.06.029
Ewald J, Rivieccio F, Radosa L, Schuster S, Brakhage AA, Kaleta C. Dynamic optimization reveals alveolar epithelial cells as key mediators of host defense in invasive aspergillosis. PLoS Comput Biol. 2021;17(12): e1009645.
pubmed: 34898608
pmcid: 8699926
doi: 10.1371/journal.pcbi.1009645
Tanaka RJ, Boon NJ, Vrcelj K, Nguyen A, Vinci C, Armstrong-James D, et al. In silico modeling of spore inhalation reveals fungal persistence following low dose exposure. Sci Rep. 2015;5:13958.
pubmed: 26364644
pmcid: 4568477
doi: 10.1038/srep13958
De Castro PA, Colabardini AC, Moraes M, Horta MAC, Knowles SL, Raja HA, et al. Regulation of gliotoxin biosynthesis and protection in Aspergillus species. PLoS Genet. 2022;18(1): e1009965.
pubmed: 35041649
pmcid: 8797188
doi: 10.1371/journal.pgen.1009965
Margalit A, Carolan JC, Kavanagh K. Bacterial interactions with Aspergillus fumigatus in the immunocompromised lung. Microorganisms. 2021;9(2):435.
pubmed: 33669831
pmcid: 7923216
doi: 10.3390/microorganisms9020435
Peng F, Zhang MY, Hou SY, Chen J, Wu YY, Zhang YX. Insights into Streptomyces spp. isolated from the rhizospheric soil of Panax notoginseng: isolation, antimicrobial activity and biosynthetic potential for polyketides and non-ribosomal peptides. BMC Microbiol. 2020;20:1.
doi: 10.1186/s12866-020-01832-5
van de Sande WWJ, Vonk AG. Mycovirus therapy for invasive pulmonary aspergillosis? Med Mycol. 2019;57(2):S179–88.
pubmed: 30816971
doi: 10.1093/mmy/myy073
Briard B, Mislin GLA, Latgé JP, Beauvais A. Interactions between Aspergillus fumigatus and pulmonary bacteria: current state of the field, new data, and future perspective. J Fungi. 2019;5(2):48.
doi: 10.3390/jof5020048
Marsland BJ, Gollwitzer ES. Host–microorganism interactions in lung diseases. Nat Rev Immunol. 2014;14(12):827–35.
pubmed: 25421702
doi: 10.1038/nri3769
Guo Y, Chen X, Gong P, Li G, Yao W, Yang W. The gut-organ-axis concept: advances the application of gut-on-chip technology. Int J Mol Sci. 2023;24(4):4089.
pubmed: 36835499
pmcid: 9962350
doi: 10.3390/ijms24044089
McAleer JP, Nguyen NLH, Chen K, Kumar P, Ricks DM, Binnie M, et al. Pulmonary Th17 antifungal immunity is regulated by the gut microbiome. J Immunol. 2016;197(1):97–107.
pubmed: 27217583
doi: 10.4049/jimmunol.1502566
Ubags NDJ, Marsland BJ. Mechanistic insight into the function of the microbiome in lung diseases. Eur Respir J. 2017;50(3):1602467.
pubmed: 28893867
doi: 10.1183/13993003.02467-2016
Mowat E, Rajendran R, Williams C, McCulloch E, Jones B, Lang S, et al. Pseudomonas aeruginosa and their small diffusible extracellular molecules inhibit Aspergillus fumigatus biofilm formation. FEMS Microbiol Lett. 2010;313(2):96–102.
pubmed: 20964704
doi: 10.1111/j.1574-6968.2010.02130.x
Briard B, Bomme P, Lechner BE, Mislin GLA, Lair V, Prévost MC, et al. Pseudomonas aeruginosa manipulates redox and iron homeostasis of its microbiota partner Aspergillus fumigatus via phenazines. Sci Rep. 2015;5:8220.
pubmed: 25665925
pmcid: 5389140
doi: 10.1038/srep08220
Zheng H, Kim J, Liew M, Yan John K, Herrera O, Bok J, et al. Redox metabolites signal polymicrobial biofilm development via the NapA oxidative stress cascade in Aspergillus. Curr Biol. 2015;25(1):29–37.
pubmed: 25532893
doi: 10.1016/j.cub.2014.11.018
Briard B, Heddergott C, Latgé JP. Volatile compounds emitted by Pseudomonas aeruginosa stimulate growth of the fungal pathogen Aspergillus fumigatus. MBio. 2016;7(2):e00219.
pubmed: 26980832
pmcid: 4807360
doi: 10.1128/mBio.00219-16
Heddergott C, Calvo AM, Latgé JP. The volatome of Aspergillus fumigatus. Eukaryot Cell. 2014;13(8):1014–25.
pubmed: 24906414
pmcid: 4135790
doi: 10.1128/EC.00074-14
Reece E, Segurado R, Jackson A, McClean S, Renwick J, Greally P. Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: an Irish registry analysis. BMC Pulm Med. 2017;17(1):70.
pubmed: 28431569
pmcid: 5401475
doi: 10.1186/s12890-017-0416-4
Amin R, Dupuis A, Aaron SD, Ratjen F. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest. 2010;137(1):171–6.
pubmed: 19567494
doi: 10.1378/chest.09-1103
Marchac V, Equi A, Le Bihan-Benjamin C, Hodson M, Bush A. Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients. Eur Respir J. 2004;23(1):98–102.
pubmed: 14738239
doi: 10.1183/09031936.03.00007203
Melloul E, Luiggi S, Anaïs L, Arné P, Costa JM, Fihman V, et al. Characteristics of Aspergillus fumigatus in association with Stenotrophomonas maltophilia in an in vitro model of mixed biofilm. PLoS ONE. 2016;11(11): e0166325.
pubmed: 27870863
pmcid: 5117647
doi: 10.1371/journal.pone.0166325
Ramírez Granillo A, Canales MGM, Espíndola MES, Martínez Rivera MA, de Lucio VMB, Tovar AVR. Antibiosis interaction of Staphylococccus aureus on Aspergillus fumigatus assessed in vitro by mixed biofilm formation. BMC Microbiol. 2015;1:15.
Boase S, Jervis-Bardy J, Cleland E, Pant H, Tan L, Wormald PJ. Bacterial-induced epithelial damage promotes fungal biofilm formation in a sheep model of sinusitis. Int Forum Allergy Rhinol. 2013;3(5):341–8.
pubmed: 23307805
doi: 10.1002/alr.21138
Monin L, Mehta S, Elsegeiny W, Gopal R, McAleer JP, Oury TD, et al. Aspergillus fumigatus preexposure worsens pathology and improves control of Mycobacterium abscessus pulmonary infection in mice. Infect Immun. 2018;86(3):e00859-e917.
pubmed: 29263106
pmcid: 5820964
doi: 10.1128/IAI.00859-17
Hérivaux A, Willis JR, Mercier T, Lagrou K, Gonçalves SM, Gonçales RA, et al. Lung microbiota predict invasive pulmonary aspergillosis and its outcome in immunocompromised patients. Thorax. 2022;77(3):283–91.
pubmed: 34172558
doi: 10.1136/thoraxjnl-2020-216179
Prosser JI, Bohannan BJM, Curtis TP, Ellis RJ, Firestone MK, Freckleton RP, et al. The role of ecological theory in microbial ecology. Nat Rev Microbiol. 2007;5(5):384–92.
pubmed: 17435792
doi: 10.1038/nrmicro1643
Fando JL, Alaba I, Escarmis C, Fernandez-Luna JL, Mendez E, Salinas M. The mode of action of restrictocin and mitogillin on eucaryotic ribosomes. Inhibition of brain protein synthesis, cleavage and sequence of the ribosomal RNA fragment. Eur J Biochem. 1985;49:29–34.
doi: 10.1111/j.1432-1033.1985.tb08888.x
de Almeida ÂB, Corrêa IP, Furuie JL, de Farias Pires T, do Rocio Dalzoto P, Pimentel IC. Inhibition of growth and ochratoxin A production in Aspergillus species by fungi isolated from coffee beans. Brazil J Microbiol. 2019;50(4):1091–8.
doi: 10.1007/s42770-019-00152-9
Kim YG, Udayanga K, Totsuka N, Weinberg Jason B, Núñez G, Shibuya A. Gut dysbiosis promotes M2 macrophage polarization and allergic airway inflammation via fungi-induced PGE2. Cell Host Microbe. 2014;15(1):95–102.
pubmed: 24439901
pmcid: 3957200
doi: 10.1016/j.chom.2013.12.010
Smeekens SP, van de Veerdonk FL, van der Meer JWM, Kullberg BJ, Joosten LAB, Netea MG. The Candida Th17 response is dependent on mannan- and -glucan-induced prostaglandin E2. Int Immunol. 2010;22(11):889–95.
pubmed: 21059767
doi: 10.1093/intimm/dxq442
Bacher P, Hohnstein T, Beerbaum E, Röcker M, Blango MG, Kaufmann S, et al. Human anti-fungal Th17 immunity and pathology rely on cross-reactivity against Candida albicans. Cell. 2019;176(6):1340–55.
pubmed: 30799037
doi: 10.1016/j.cell.2019.01.041
Cai L, Gao P, Wang Z, Dai C, Ning Y, Ilkit M, et al. Lung and gut microbiomes in pulmonary aspergillosis: exploring adjunctive therapies to combat the disease. Front Immunol. 2022;13: 988708.
pubmed: 36032147
pmcid: 9411651
doi: 10.3389/fimmu.2022.988708
Gallo A, Perrone G, Solfrizzo M, Epifani F, Alan AA, et al. Characterisation of a pks gene which is expressed during ochratoxin A production by Aspergillus carbonarius. Int J Food Microbiol. 2009;129(1):8–15.
pubmed: 19038469
doi: 10.1016/j.ijfoodmicro.2008.10.022
Leoni B, Maria Paulo L. Ochratoxin A in Brazilian roasted and instant coffees. Food Addit Contam. 2000;17(10):867–70.
pubmed: 11103271
doi: 10.1080/026520300420448
Batista LR, Chalfoun SM, Silva CF, Cirillo M, Varga EA, Schwan RF. Ochratoxin A in coffee beans (Coffea arabica) processed by dry and wet methods. Food Control. 2009;20(9):784.
doi: 10.1016/j.foodcont.2008.10.003
Cho SY, Lee DG, Choi JK, Lee HJ, Kim SH, Park SH, et al. Characteristics of culture-positive invasive pulmonary aspergillosis in patients with hematologic diseases: comparison between Aspergillus fumigatus and non-fumigatus Aspergillus species. Medicine (Baltimore). 2017;96(49): e8841.
pubmed: 29245249
doi: 10.1097/MD.0000000000008841
Flygare S, Simmon K, Miller C, Qiao Y, Kennedy B, Di Sera T, et al. Taxonomer: an interactive metagenomics analysis portal for universal pathogen detection and host mRNA expression profiling. Genome Biol. 2016;17(1):111.
pubmed: 27224977
pmcid: 4880956
doi: 10.1186/s13059-016-0969-1
Rick EM, Woolnough KF, Seear PJ, Fairs A, Satchwell J, Richardson M, et al. The airway fungal microbiome in asthma. Clin Exp Allergy. 2020;50(12):1325–41.
pubmed: 32808353
doi: 10.1111/cea.13722
Sabino R, Gonçalves P, Martins Melo A, Simões D, Oliveira M, Francisco M, et al. Trends on Aspergillus epidemiology-perspectives from a national reference laboratory surveillance program. J Fungi (Basel). 2021;7(1):28.
pubmed: 33418997
doi: 10.3390/jof7010028
Nash AK, Auchtung TA, Wong MC, Smith DP, Gesell JR, Ross MC, Stewart CJ, Metcalf GA, Muzny DM, Gibbs RA, Ajami NJ, Petrosino JF. The gut mycobiome of the human microbiome project healthy cohort. Microbiome. 2017;5(1):153.
pubmed: 29178920
pmcid: 5702186
doi: 10.1186/s40168-017-0373-4
Nguyen LD, Viscogliosi E, Delhaes L. The lung mycobiome: an emerging field of the human respiratory microbiome. Front Microbiol. 2015;6:89.
pubmed: 25762987
pmcid: 4327734
doi: 10.3389/fmicb.2015.00089
Kröner C, Kappler M, Grimmelt AC, Laniado G, Würstl B, Griese M. The basidiomycetous yeast Trichosporon may cause severe lung exacerbation in cystic fibrosis patients—clinical analysis of Trichosporon positive patients in a Munich cohort. BMC Pulm Med. 2013;13:61.
pubmed: 24180379
pmcid: 4228431
doi: 10.1186/1471-2466-13-61
Filipe R, Caldas JP, Soares N, Sabino R, Veríssimo C, Silva R, Silva-Pinto A, Tavares M, Sarmento A. Schizophyllum commune sphenoidal sinusitis as presentation of a non-Hodgkin Lymphoma. Med Mycol Case Rep. 2020;28:26–8.
pubmed: 32322473
pmcid: 7162964
doi: 10.1016/j.mmcr.2020.04.003